The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

In this piece, we will look at where GSK plc (NYSE:GSK) ranks among the top ten global stocks ... but with interest rate cuts ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Lawyers representing 10 groups of plaintiffs, or 80,000 liability cases across the US, have backed the payout. There remain another few thousand cases not covered by the payout. GSK will also pay a ...

European stocks inched higher on Thursday, tracking Asian peers on hopes of more stimulus in China, while investors awaited U ...

SG Americas Securities LLC increased its position in GSK plc (NYSE:GSK – Free Report) by 167.3% in the third quarter, ...

GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...

GSK's ViiV Healthcare has suspended development of a Phase 2-stage HIV antiviral named VH3739937, a GSK spokesperson ...

With one eye on the French government's 2025 budget later on Thursday - which is set to deliver some 60 billion euros ($65.68 ...

GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...